Hormone Replacement Therapy and Venous Disease

References

• Koh K. K., Home M. K. I., Csako G., Waclawiw M. A., Cannon R. O. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol, 1999, 83: 466–69.
   Google Scholar
• Herrington D. M., Klein K. P. Genome and hormones: gender differences in physiology. Invited review: pharmacogenetics of estrogen replacement therapy. J Appl Physiol, 2001, 91: 2776–84.
   Google Scholar
• Rosendaal F. R., Helmerhost F. M., Vanderbroucke J. P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol, 2002, 22: 201–10.
   Google Scholar
• Hoibraaten E., Qvigstad E., Anderesen T. O., Mowinckel M. C., Sandset P. M. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous throm-boembolism — results from a randomized, double — blind, clinical trial. Thromb Haemost, 2001, 85: 775–81.
   Google Scholar
• Rosendaal F. R., Helmerhost F. M., Vandenbroucke J. P. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost, 2001, 86: 112–23.
   Google Scholar
• Grodstein F., Stampfer M. J., Goldhaber S. Z. et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet, 1996, 348: 983–87.
   Google Scholar
• Daly E., Vessey M. P., Painter R., Hawkins M. M. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet, 1996, 348: 1027.
   Google Scholar
• Varas Lourenzo C., Garcia Rodrigues L. A., Cattaruzzi C., Troncon M. G., Agostinis L., Perez Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population — based study in southern Europe. Am J Epidemiol, 1998, 147: 387–90.
   Google Scholar
• Grady D., Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA, 1997, 278: 477.
   Google Scholar
• Grady D., Wenger N. K., Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Int Med, 2000, 132: 689–96.
   Google Scholar
• Hoibraaten E., Abdelnoor M., Sandset P. M. Hormone replacement therapy with estradiol and risk of venous thromboembo-lism: a population-based case — control study. Thromb Haemost, 1999, 82: 1218–21.
   Google Scholar
• Daly E., Vessey M. P., Hawkins M. W., Carson J. L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet, 1996, 348: 977–80.
   Google Scholar
• Rivas Yepez J. A., Freire C. M. V., Almeida M. C. C., Souza P. M. T. Trombose venosa, fenomenos tromboembolicos e terapeutica de reposijao hormonal. Cir VascAngiol, 1998, 14: 3337.
   Google Scholar
• Konkle B. A. Thrombophilic states in women — special concerns. Hematology (Am Soc Hematol Educ Program), 2001, 325–30.
   Google Scholar
• Hulley S., Grady D., Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA, 1998, 280: 605–13.
   Google Scholar
• Women’s Health Initiative (WHI) Data and Safety Monitoring Board (DSMB) Statement reported in WHI HRT Update June, 2002. Available at www.whi.org/update/2002update.
   Google Scholar
• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA, 2002, 288: 321–33.
   Google Scholar
• Miller J., Chan B. K., Nelson H. D. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med, 2002, 136: 680–90.
   Google Scholar
• U.S. Preventive Services Task Force. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendation Statement. AHRQ Publication No. 05–0576, May, 2005. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf05/ht/htpost-menrs.htm, Ann Intern Med, 2005, 142: 855–860.
   Google Scholar
• Rosendaal F. R., Vessey M., Rumley A. et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol, 2002, 116: 851–4.
   Google Scholar
• Herrington D. M., Vittinghoff E., Howard T. D. et al. Factor V Leiden, hormone replacement therapy and risk of thromboembol-ic events in women with coronary disease. Arterioscler Thromb Vasc Biol, 2002, 22: 1012–17.
   Google Scholar
• Orimo A., Inoue S., Ikegami A., Hosoi T., Akishita M., Ouchi Y., Muramatsu M., Orimo H. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun, 1993 ,15, 195: 7306.
   Google Scholar
• Knaapen M. W., Somers P., Bortier H., De Meyer G. R., Kockx M. M. Smooth muscle cell hypertrophy in varicose veins is associated with expression of estrogen receptor-beta. J Vasc Res, 2005, 42: 8–12.
   Google Scholar
• Mashiah A., Berman V., Thole H. H., Rose S. S., Pasik S., Schwarz H., Ben-Hur H. Estrogen and progesterone receptors in normal and varicose saphenous veins. Cardiovasc Surg, 1999, 7: 327–31.
   Google Scholar
• Varbiro S., Nadasy G. L., Monos E., Acs N., Vajo Z., Szekacs B. sex hormone replacement therapy reverses decreased venous dis-tensibility in pharmacologically ovariectomized rats. Menopause, 2001, 8: 204–9. 3.
   Google Scholar
• Ashworth J. J., Smyth J. V., Pendleton N. et al. The dinucleotide (CA) repeat polymorphism of estrogen receptor beta but not the dinucleotide (TA) repeat polymorphism of estrogen receptor alpha is associated with venous ulceration. J Steroid Biochem Mol Biol, 2005, 97: 266–70.
   Google Scholar
• Margolis D. J., Knauss J., Bilker W. Hormone replacement therapy and prevention of pressure ulcers and venous leg ulcers. Lancet, 2002, 359 (9307): 675–7.
   Google Scholar
• Berard A., Kahn S. R., Abenhaim L. Is hormone replacement therapy protective for venous ulcer of the lower limbs ? Pharmacoepidemiol Drug Saf, 2001, 10: 245–51.
   Google Scholar
• Prentice R. L., Langer R. D., Stefanick M. L. et al., Women’s Health Initiative Investigators. Combined analysis of Women’s Health Initiative observational and clinical trial data on post-menopausal hormone treatment and cardiovascular disease. Am J Epidemiol, 2006, 163: 589–99.
   Google Scholar
• Lam P. M., Chung T. K., Haines C. Where are we with post-menopausal hormone therapy in, 2005 ? Gynecol Endocrinol, 2005, 21: 248–56.
   Google Scholar
• Ness J., Aronow W. S., Newkirk E., McDanel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women’s Health Initiative Trial. J Gerontol A Biol Sci Med Sci, 2005, 60: 460–2.
   Google Scholar